Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-33.66 Insider Own7.10% Shs Outstand8.79M Perf Week0.73%
Market Cap366.02M Forward P/E- EPS next Y-10.04 Insider Trans2.38% Shs Float8.17M Perf Month11.97%
Income-137.57M PEG- EPS next Q-3.05 Inst Own85.63% Short Float6.90% Perf Quarter159.44%
Sales1.93M P/S189.65 EPS this Y70.65% Inst Trans-8.33% Short Ratio3.91 Perf Half Y86.31%
Book/sh10.12 P/B4.11 EPS next Y50.86% ROA-112.94% Short Interest0.56M Perf Year-17.63%
Cash/sh11.50 P/C3.62 EPS next 5Y-14.60% ROE-143.36% 52W Range11.85 - 54.22 Perf YTD86.89%
Dividend Est.- P/FCF- EPS past 5Y-57.01% ROI-155.59% 52W High-23.20% Beta2.81
Dividend TTM- Quick Ratio6.15 Sales past 5Y0.00% Gross Margin35.77% 52W Low251.39% ATR (14)3.10
Dividend Ex-Date- Current Ratio6.15 EPS Y/Y TTM55.97% Oper. Margin-7247.41% RSI (14)55.99 Volatility5.04% 7.79%
Employees109 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin-7120.70% Recom1.33 Target Price125.80
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q81.08% Payout- Rel Volume0.59 Prev Close40.33
Sales Surprise- EPS Surprise30.77% Sales Q/Q- EarningsNov 07 BMO Avg Volume144.31K Price41.64
SMA20-0.46% SMA5025.05% SMA20092.86% Trades Volume84,664 Change3.25%
Date Action Analyst Rating Change Price Target Change
Sep-19-23Initiated Truist Buy $10
Jun-06-22Downgrade Wedbush Outperform → Neutral $4
Dec-16-21Initiated H.C. Wainwright Buy $48
Aug-26-21Initiated BofA Securities Buy $28
Apr-26-21Initiated William Blair Outperform
Nov-11-20Initiated Wedbush Outperform $40
Nov-10-20Initiated Piper Sandler Overweight $65
Nov-10-20Initiated Evercore ISI Outperform $55
Nov-10-20Initiated Cowen Outperform
Feb-02-24 04:00PM
Jan-11-24 07:30AM
Jan-10-24 04:19PM
Jan-09-24 04:57PM
Jan-08-24 08:00AM
09:55AM Loading…
Jan-05-24 09:55AM
Nov-30-23 09:55AM
Nov-28-23 07:00AM
Nov-21-23 04:00PM
Nov-16-23 08:00AM
Nov-14-23 09:35AM
Nov-07-23 08:00AM
Nov-02-23 08:00AM
01:17PM Loading…
Oct-02-23 01:17PM
Sep-27-23 04:15PM
Sep-07-23 08:00AM
Aug-31-23 08:00AM
Aug-28-23 07:00AM
Aug-17-23 10:04AM
Aug-11-23 07:00AM
Aug-09-23 07:00AM
Aug-08-23 07:00AM
Aug-07-23 07:00AM
Aug-03-23 04:12PM
Jul-14-23 10:20AM
Jun-22-23 07:00AM
Jun-17-23 09:41AM
Jun-15-23 11:58PM
04:01PM Loading…
Jun-09-23 07:00AM
Jun-02-23 09:00AM
May-11-23 01:12PM
May-07-23 09:22AM
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-06-23 09:00AM
Mar-03-23 04:05PM
Feb-07-23 08:00AM
Dec-13-22 04:01PM
Nov-28-22 04:05PM
Nov-09-22 04:01PM
Nov-07-22 09:00AM
Sep-26-22 06:28AM
Sep-21-22 09:00AM
Sep-20-22 08:30AM
Sep-07-22 04:05PM
Aug-08-22 04:01PM
Aug-03-22 09:00AM
Jul-11-22 02:20PM
Jun-26-22 09:47AM
Jun-07-22 11:30AM
Jun-06-22 08:39AM
May-23-22 09:00AM
May-13-22 12:54PM
May-11-22 09:00AM
May-10-22 08:22AM
May-09-22 04:01PM
May-04-22 09:00AM
May-02-22 04:15PM
Apr-27-22 08:25AM
Apr-18-22 03:08PM
Apr-13-22 08:00AM
Apr-01-22 09:00AM
Mar-21-22 09:00AM
Mar-01-22 09:00AM
Feb-28-22 06:00AM
Feb-22-22 09:00AM
Jan-18-22 09:00AM
Jan-17-22 09:07AM
Dec-10-21 11:00AM
Dec-02-21 07:00AM
Nov-29-21 08:00AM
Nov-24-21 09:00AM
Nov-08-21 12:00PM
Nov-03-21 07:00AM
Oct-29-21 09:12AM
Oct-22-21 09:00AM
Oct-19-21 10:34AM
Sep-01-21 09:00AM
Aug-16-21 08:00AM
Aug-02-21 09:00AM
Jul-19-21 08:27AM
Jul-06-21 09:00AM
May-25-21 08:00AM
May-14-21 09:00AM
May-13-21 10:39PM
May-11-21 04:22PM
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeSimone JillDirectorOct 05Buy1.7514,50025,37514,500Oct 10 07:41 AM
Souza MarcioChief Executive OfficerJun 27Buy1.0610,00010,58745,002Jun 27 07:52 PM
MITCHELL DEAN JDirectorMar 24Buy0.8450,00041,81575,000Mar 27 01:11 PM
Souza MarcioChief Executive OfficerMar 23Buy0.8635,00230,20735,002Mar 27 01:12 PM
Souza MarcioChief Executive OfficerMar 23Buy0.8635,00030,160226,299Mar 27 01:12 PM